A Phase II trial of tandutinib (MLN 518) in combination with bevacizumab for patients with recurrent glioblastoma Article

Odia, Y, Sul, J, Shih, JH et al. (2016). A Phase II trial of tandutinib (MLN 518) in combination with bevacizumab for patients with recurrent glioblastoma . 5(2), 59-67. 10.2217/cns-2015-0010

cited authors

  • Odia, Y; Sul, J; Shih, JH; Kreisl, TN; Butman, JA; Iwamoto, FM; Fine, HA

authors

abstract

  • AIM: A Phase II trial of bevacizumab plus tandutinib.

publication date

  • January 1, 2016

Digital Object Identifier (DOI)

start page

  • 59

end page

  • 67

volume

  • 5

issue

  • 2